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Abstract 
 
The psychedelic properties of lysergic acid diethylamide (LSD) have captured the 
imagination of researchers for many years and its rediscovery as an important 
research tool is evidenced by its clinical use within neuroscientific and therapeutic 
settings. At the same time, a number of novel LSD analogs have recently emerged 
as recreational drugs, which makes it necessary to study their analytical and 
pharmacological properties. One of the most recent additions to this series of LSD 
analogs is 1-butanoyl-LSD (1B-LSD), a constitutional isomer of 1-propionyl-6-ethyl-6-
nor-lysergic acid diethylamide (1P-ETH-LAD), another LSD analog that was 
described previously. This study presents a comprehensive analytical 
characterization of 1B-LSD employing nuclear magnetic resonance spectroscopy 
(NMR), low- and high-resolution mass spectrometry platforms, gas- and liquid 
chromatography (GC and LC), and GC-condensed phase and attenuated total 
reflection infrared spectroscopy analyses. Analytical differentiation of 1B-LSD from 
1P-ETH-LAD was straightforward. LSD and other serotonergic hallucinogens induce 
the head-twitch response (HTR) in rats and mice, which is mediated by 5-HT2A 
receptor activation. HTR studies were conducted in C57BL/6J mice to assess 
whether 1B-LSD has LSD-like behavioral effects. 1B-LSD produced a dose-
dependent increase in HTR counts, acting with ~14% (ED50 = 976.7 nmol/kg) of the 
potency of LSD (ED50 = 132.8 nmol/kg). This finding suggests that the behavioral 
effects of 1B-LSD are reminiscent of LSD and other serotonergic hallucinogens. The 
possibility exists that 1B-LSD serves as a pro-drug for LSD. Further investigations 
are warranted to confirm whether 1B-LSD produces LSD-like psychoactive effects in 
humans. 
 
1. Introduction 
 
The serotonergic hallucinogen lysergic acid diethylamide (LSD, Figure 1) is one of 
the most potent psychedelic drugs, with typical oral doses ranging from 50–200 µg1 
although lower doses can be found on blotters circulating on the streets. Use of LSD 
has occurred at relatively constant levels since the end of the 1960s and it remains a 
popular recreational substance due to nature and intensity of its psychedelic effects.2 
More recently, widespread interest in the use of LSD at sub-threshold levels (so-
called “microdosing”) has developed, based on anecdotal accounts indicating that 
very low doses of the drug may have performance-enhancing and other beneficial 
effects.3 In addition, a large number of promising clinical studies have been 
conducted in recent years to explore the use of LSD for neuroscientific and 
therapeutic purposes.4,5 
 
Various substitutions on the indole nitrogen (position N1) of LSD were prepared in 
previous decades, including the attachment of acyl groups.6,7 One of the earliest 
examples is 1-acetyl-LSD (ALD-52, 1A-LSD; Figure 1), which has LSD-like 
psychoactive properties in humans.8-11 It was recently shown that ALD-52 is 
hydrolyzed to LSD when incubated with pooled human liver enzymes, indicating that 
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it may serve as a prodrug for LSD in vivo.12 Clinical investigations with ALD-52 are 
ultimately necessary to confirm the extent of LSD formation in humans. According to 
the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), ALD-52 
was first detected in Europe in April 201613 whereas the detection of 1-propanoyl-
LSD (1P-LSD, Figure 1) was notified in 2015.14 1P-LSD and 1P-ETH-LAD (Figure 1), 
two other 1-acyl substituted lysergamides that have been marketed online as 
recreational drugs in recent years, were also shown to undergo N-deacylation to LSD 
and ETH-LAD, respectively.12,15,16 ETH-LAD appears to produce psychedelic effects 
in humans1,17 and was shown to be more potent than LSD in rats trained to 
discriminate the latter drug from saline.18 1-Butanoyl-LSD (1B-LSD, (6aR,9R)-4-
butanoyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-
carboxamide; Figure 1) is the most recent N1-acylated LSD derivative to appear on 
the recreational drug market. Similar to ALD-52, 1P-LSD, and 1P-ETH-LAD, 1B-LSD 
is hydrolyzed to LSD in vitro.12  
 
The head twitch response (HTR) is a rapid paroxysmal head movement induced by 
serotonergic hallucinogens in rats and mice via 5-HT2A receptor activation.19-21 Using 
this assay, it is possible to distinguish between hallucinogenic and non-
hallucinogenic 5-HT2A receptor agonists.21,22 Furthermore, the HTR is commonly 
used as a behavioral proxy in rodents for human hallucinogenic effects. In previous 
investigations, several lysergamides available as research chemicals, including 1P-
LSD, were found to induce the HTR.15,23,24 One exception was lysergic acid 
morpholide (LSM-775), which only induced the HTR when 5-HT1A receptors were 
blocked by pretreatment with the antagonist WAY-100,635.25 Consistent with these 
results, LSM-775 did not fully mimic the psychedelic effects produced by LSD when it 
was evaluated in humans.9,10,26  
 
In the present study, HTR experiments were conducted with 1B-LSD in C57BL/6J 
mice to determine whether it produces LSD-like behavioral effects.  A comprehensive 
analytical characterization is also included using various mass spectrometry (MS) 
platforms, gas- and liquid chromatography (GC and LC), nuclear magnetic 
resonance spectroscopy (NMR) and GC condensed phase infrared (IR) analysis. 
These analytical data are being made available to other investigators who encounter 
this newly emerging psychoactive substance. 
 
2. Experimental 
 
2.1 Materials 
 
All chemicals used were of analytical and HPLC grade and obtained from Aldrich 
(Dorset, UK). DMSO-d6 (99.8% D) was from VWR (Leicestershire, UK). 1-Butanoyl-
LSD hemitartrate (2:1) powder (1B-LSD) was supplied by Synex Synthetics BV, 
Maastricht, The Netherlands. 
 
2.2 Instrumentation 
 
2.2.1 Gas chromatography mass spectrometry  
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Electron ionization (EI) mass spectra (70 eV) were recorded using a Finnigan TSQ 
8000 EVO triple stage quadrupole mass spectrometer coupled to a gas 
chromatograph (Trace 1310, Thermo Electron, Dreieich, Germany). Sample 
introduction was carried out using a Triplus RSH autosampler. The emission current 
was 200 µA and the scan time was 1 s spanning a scan range between m/z 29–600. 
The ion source temperature was maintained at 220°C. Samples were introduced via 
gas chromatography with splitless injection using a fused silica capillary DB-1 column 
(30 m × 0.25 mm, film thickness 0.25 µm). The temperature program consisted of an 
initial temperature of 80°C, held for 2 min, followed by a ramp to 310°C at 20°C/min. 
The final temperature was held for 23 min. The injector temperature and the transfer 
line temperature were 280°C and 300°C and the carrier gas was helium in constant 
flow mode at a flow rate of 1.2 mL/min. Approximately 2 mg were dissolved in 1.5 mL 
methanol. For analysis, 1 µL of sample solution was injected into the GC-MS system. 
Kovats retention indices (RI) were calculated from measurement of an n-alkane 
mixture analyzed with the above-mentioned temperature program. 
 
2.2.2 Gas chromatography solid-state infrared analysis 
 
Samples were analyzed using a GC-solid phase-IR-system that consisted of an 
Agilent GC 7890B (Waldbronn, Germany) with probe sampler Agilent G4567A and a 
DiscovIR-GC™ (Spectra Analysis, Marlborough, MA, USA). The column eluent was 
cryogenically accumulated on a spirally rotating ZnSe disk cooled by liquid nitrogen. 
IR spectra were recorded through the IR-transparent ZnSe disk using a nitrogen-
cooled MCT detector. GC parameters: injection in splitless mode with the injection 
port temperature set at 240°C and a DB-1 fused silica capillary column (30 m × 
0.32 mm i.d., 0.25 µm film thickness). The carrier gas was helium with a flow rate of 
2.5 mL/min and the oven temperature program was as follows: 80°C for 2 min, 
ramped to 310°C at 20 °C/min, and held at for 23 min. The transfer line was heated 
at 280°C. Infrared conditions: oven temperature, restrictor temperature, disc 
temperature, and Dewar cap temperatures were 280°C, 280°C, -40°C, and 35°C, 
respectively. The vacuum was 0.2 mTorr, disc speed 3 mm/s, spiral separation was 1 
mm, wavelength resolution 4 cm-1 and IR range 650–4000 cm-1. Acquisition time was 
0.6 s/file with 64 scans/spectrum. Data were processed using GRAMS/AI Ver. 9.1 
(Grams Spectroscopy Software Suite, Thermo Fisher Scientific, Dreieich, Germany) 
followed by implementation of the OMNIC Software, Ver. 7.4.127 (Thermo Electron 
Corporation, Dreieich, Germany). 
 
2.2.3 High mass accuracy electrospray ionization mass spectrometry  
Ultrahigh-performance liquid chromatography quadrupole time-of-flight single and 
tandem mass spectrometry (UHPLC-QTOF-MS/MS) data were obtained from an 
Agilent 6540 UHD Accurate-Mass QTOF LC-MS system coupled to an Agilent 1290 
Infinity UHPLC system (Agilent, Cheshire, UK). Separation was achieved using an 
Agilent Zorbax Eclipse Plus C18 column (100 mm × 2.1 mm, 1.8 µm) (Agilent, 
Cheadle, UK). Mobile phases consisted of acetonitrile (1% formic acid) and 1% 
formic acid in water. The column temperature was set at 40°C (0.6 mL/min) and data 
were acquired for 5.5 min. The gradient was set at 5–70% acetonitrile over 3.5 min, 
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then increased to 95% acetonitrile in 1 min and held for 0.5 min before returning to 
5% acetonitrile in 0.5 min. QTOF-MS data were acquired in positive mode scanning 
from m/z 100–1000 with and without auto MS/MS fragmentation. Ionization was 
achieved with an Agilent JetStream electrospray source and infused internal 
reference masses. QTOF-MS parameters: gas temperature 325°C, drying gas 10 
L/min and sheath gas temperature 400°C. Internal reference ions at m/z 121.05087 
and m/z 922.00979 were used for calibration purposes.   
 
2.2.4 Liquid chromatography electrospray ionization mass spectrometry 
HPLC single quadrupole mass spectrometry (LC-Q-MS) analyses were carried out 
on an Agilent 1100 system using a Restek (Bellefonte, PA, USA) Allure PFPP 
column (5 µm, 50 × 2.1 mm). The aqueous mobile phase A consisted of 0.1% formic 
acid, whereas, mobile phase B consisted of 0.1% formic acid in acetonitrile. The total 
run time was 25 min. The following gradient elution program was used: 0–2 min 2% 
B, followed by an increase to 60% within 15 min, then up to 80% within 20 min, 
returning to 2% within 25 min. The Agilent LC-MSD settings were as follows: positive 
electrospray mode, capillary voltage 3500 V, drying gas (N2) 12 L/min at 350°C, 
nebulizer gas (N2) pressure 50 psi, scan mode m/z 70–500, fragmentor voltage 
values used for in-source collision-induced dissociation (CID) were 30 V and 150 V, 
respectively. The sample was dissolved in acetonitrile/water (1:1, containing 0.1% 
formic acid) at a concentration of 10 µg/mL. The injection volume was 1 µL, flow rate 
was 0.80 mL/min and the column temperature was 30°C.  
2.2.5 High performance liquid chromatography diode array detection 
A Dionex 3000 Ultimate liquid chromatography system coupled to a UV diode array 
detector (Thermo Fisher, St. Albans, UK) was used using a Phenomenex Synergi 
Fusion column (150 mm × 2 mm, 4 µm) protected by a 4 mm × 3 mm Phenomenex 
Synergi Fusion guard column (Phenomenex, Macclesfield, UK). The mobile phases 
were 70% acetonitrile with 25 mM of triethylammonium phosphate buffer (TEAP) (B) 
and aqueous TEAP (25 mM) buffer (A). The gradient elution commenced with 4% B 
and ramped to 70% B in 15 min and held for 3 min, resulting in a total acquisition 
time of 18 min at a flow rate of 0.6 mL/min. The diode array detection window was 
set at 200–595 nm (collection rate 2 Hz). 
2.2.6 Nuclear magnetic resonance (NMR) spectroscopy 
 
Samples were prepared in deuterated dimethyl sulfoxide (DMSO-d6) and 1H (600 
MHz) and 13C (150 MHz) spectra were recorded on a Bruker AVANCE III 600 MHz 
NMR spectrometer. Spectra were referenced to residual solvent and assignments 
were supported by both 1D and 2D experiments.   
 
2.3 Animal pharmacology  
 
Male C57BL/6J mice (6−8 weeks old) were obtained from Jackson Laboratories (Bar 
Harbor, ME, USA) and housed up to four per cage with a reversed light-cycle (lights 
on at 1900 h, off at 0700 h). Food and water were provided ad libitum, except during 
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behavioral testing. Testing was conducted between 1000 and 1830 h. The head 
twitch response (HTR) was detected using a head mounted magnet and a 
magnetometer coil.21,27 Mice received intraperitoneal (IP) vehicle (saline) or 1B-LSD 
(0.025, 0.05, 0.1, 0.2, 0.4, or 0.8 mg/kg) and then HTR was assessed for 30 min.   
The injection volume was 5 mL/kg.  
 
2.3.1 Analysis 
 
Head twitches were detected as described in previous experiments.21,27 Head twitch 
counts were analyzed using one-way analyses of variance (ANOVA). Post-hoc 
comparisons were made using Tukey’s studentized range method. Significance was 
demonstrated by surpassing an α-level of 0.05. ED50 values and 95% confidence 
intervals were calculated using nonlinear regression. Potency values were compared 
using an extra-sum-of-squares F-test. 
 
3. Results and discussion 
 
3.1 Analytical features  
 
The electron ionization (EI) mass spectrum of 1B-LSD is shown in Figure 2 followed 
by proposed fragmentation pathways (Figure 3) based on previous investigations 
with a range of related lysergamides. For example, fragments typically recorded with 
compounds of this class include fragment clusters at m/z 151–156, m/z 161–169, 
m/z 178–182, m/z 191–197 and m/z 205–208.15,16,23,25,28 The following discussion of 
analytical data will focus on the difference between 1B-LSD and its isomer 1P-ETH-
LAD, which was the subject of a previous report.16   
 
The retro-Diels-Alder fragment at m/z 350 was consistent with the mass shift 
associated with the butanoyl group attached to the indole nitrogen of 1B-LSD. In 
comparison, the 1-propanoyl analogs 1P-LSD and 1P-ETH-LAD gave rise to a 
species at m/z 33615,16 reflecting the reduced chain length and mass difference of 14 
u. A further reduction in chain length would be represented by N1-acetyl-LSD (1A-
LSD, ALD-52) where the corresponding fragment was detectable at m/z 322.29 
Another N-acyl group related difference between the mass spectra of 1P-ETH-LAD 
and 1B-LSD could be observed at the low mass range of the spectrum. In 1B-LSD, a 
prominent peak was observed at m/z 43 (Figure 2) that might have been attributed to 
the formation of an n-propyl fragment, presumably following the loss of CO from the 
butanoyl ion when it was cleaved off the indole nitrogen (Figure 3). In the EI mass 
spectrum of 1P-ETH-LAD, the propanoyl ion was detected at m/z 57 instead.16 
Another notable difference between the spectra of 1B-LSD and 1P-ETH-LAD can be 
seen in fragments that reflect the different alkyl groups located on the N6 nitrogen 
atom. The EI mass spectrum of 1B-LSD revealed a LSD-type fragment cluster at m/z 
219–22428 (Figure 2) and suggested mechanisms associated with the key ions of this 
cluster have been included in Figure 3. In the cases of ETH-LAD and 1P-ETH-LAD, 
however, extending the N6-methyl to N6-ethyl led to a corresponding shift of 14 u and 
the detection of fragments at m/z 233–238.16 Similarly, the m/z 219–224 cluster was 
detected in the EI mass spectrum of lysergic acid 2,4-dimethylazetidide (LSZ, 
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containing N6-methyl) but not 6-allyl-6-nor-LSD (AL-LAD, containing N6-allyl).23 N,N-
Diethylamide related fragments (e.g. m/z 72, 100 and 128) (Figure 3) were detected 
in both 1B-LSD and 1P-ETH-LAD16, which did not contribute to their differentiation. 
From a gas chromatographic perspective, 1B-LSD (retention time 25.86 min, RI = 
3579 (DB-1, 310 °C), Figure 2) could be conveniently distinguished from 1P-ETH-
LAD (retention time 21.37 min, RI = 3529 (DB-1, 310 °C).16  
 
The infrared spectrum obtained from GC solid-state analysis is shown in Figure 4. 
The hemitartrate salt sample was converted to the free base with aqueous sodium 
hydroxide (5 % w/w) and extracted into diethyl ether and then subjected to GC 
analysis. The signals linked to the carbonyl groups (1702.0 and 1638.7 cm-1) were 
comparable to those reported for 1P-LSD (1703.7 and 1637.5 cm-1)15 and 1P-ETH-
LAD (1704.0 and 1639.7 cm-1), respectively.16 Some little but distinct and 
characteristic differences between 1B-LSD and 1P-ETH-LAD16 in the fingerprint 
region were visible. Characteristic differences were observed for example at 1339, 
1253/1244, 1051/1044, and 904/891/877 cm-1 (Supporting Information). For 
completeness, the ATR-IR spectrum recorded from the 1B-LSD hemitartrate salt has 
also been added to the Supporting Information section.  
 
Liquid chromatography-based methods confirmed that 1B-LSD could be separated 
from 1P-ETH-LAD in two out of three cases. As shown in Figure 5, the retention 
times recorded were 2.213 min (UHPLC-QTOF-MS/MS), 13.07 min (LC-Q-MS) and 
9.03 min (LC-DAD), respectively. Under identical conditions reported previously, the 
isomeric 1P-ETH-LAD eluted at 2.667, 13.05 min (LC-Q-MS) and 8.51 min (LC-
DAD).16 The observation that both isomers were not separated using the LC-Q-MS 
method was interesting. On the one hand, it was expected to observe an increase in 
lipophilicity with the addition of an additional methylene unit to the acyl group in 1B-
LSD, but it appeared that this was balanced by a loss of lipophilicity with the N6-
methyl group (1B-LSD) compared to the N6-ethyl group found in 1P-ETH-LAD. In the 
UHPLC-QTOF-MS/MS method, a Zorbax Eclipse Plus C18 column was employed 
whereas the LC-DAD method was based on a Phenomenex Synergi Fusion column 
(”polar embedded” C18 column). In case of the LC-Q-MS method, an Allure 
pentafluorophenyl propyl column was employed and the use of acetonitrile as the 
organic modifier might have had a disfavorable impact on selectivity due to potential 
disruption of π-π interactions. Employing a selected ion monitoring method under LC-
Q-MS conditions (Figure 4C) revealed that the iso-1B-LSD epimer could not be 
detected. The full scan UV spectrum recorded with the HPLC-DAD method showed a 
distinct profile (Figure 4D) comparable with the spectrum of the isomeric 1P-ETH-
LAD, which confirmed that differentiation was not possible on UV data alone.  
 
The electrospray ionization QTOF HRMS/MS and single quadrupole mass spectra 
recorded for 1B-LSD are presented in Figures 5A and 5B with the proposed 
fragmentation pathways shown in Figure 6 in accordance with those reported for 
other lysergamides.15,16,23,25 The suggested product ion representing the m/z 251 
species was based on a separate HR-MS/MS experiment and the corresponding 
spectrum has been made available in the Supporting Information section. Compared 
to the mass spectra of 1P-LSD published previously,15 some of the key product ions 
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remained the same, such as m/z 74, 100, 128, 156, 208, and 223 whereas those 
detected at m/z 293 and 351 (m/z 279 and 337 in 1P-LSD) represented the mass 
shift of 14 u signifying the additional methylene unit. A comparison with the mass 
spectra recorded for the isomer 1P-ETH-LAD16 suggested that sufficient information 
was available to facilitate differentiation. Product ions linked to the shift from N6-ethyl 
(1P-ETH-LAD) to N6-methyl (1B-LSD) included m/z 237 (1P-ETH-LAD) versus m/z 
223 (1B-LSD) and m/z 365 (1P-ETH-LAD) versus m/z 379 (1B-LSD). Another 
product ion detected both in ETH-LAD and 1P-ETH-LAD but not observed in the 
mass spectrum of 1B-LSD was m/z 58.16 This might have arisen from a retro-Diels-
Alder mechanism to form the CH2=NH+C2H5 (C3H8N+) iminium ion. In 1B-LSD, the 
equivalent species reflecting the presence of the N6-methyl group would have been 
expected to form at m/z 44 but this was not observed under the conditions used 
(Figure 5). However, the presence of m/z 58 in the QTOF-MS/MS spectrum of 1P-
ETH-LAD and its absence in 1B-LSD offered an additional differentiating feature.   
 
The nuclear magnetic resonance (NMR) spectroscopy data for 1B-LSD are 
summarized in Table 1 (full spectra are shown in the Supporting Information). The 
assignments were supported by HSQC and HMBC experiments and were essentially 
consistent with those reported previously.15,16,23,25 The spectra were comparable with 
those recorded for 1P-LSD. The additional methylene unit found in the acyl 
(butanoyl) group of 1B-LSD was reflected in the spectral information. In the 1H NMR 
spectrum, the additional methylene group (labeled here as H-25, Table 1) resonated 
at 1.73 ppm in the form of a sextet. The corresponding signal in the 13C spectrum 
was observed at 18.13 ppm. In the 1H NMR spectrum of 1P-LSD, the methyl groups 
associated with the amide and acyl groups did partially overlap whereas in 1B-LSD, 
all three triplets were sufficiently resolved at 1.19, 1.07 and 1.00 ppm. In 1P-LSD 
(and also 1P-ETH-LAD) the indole H-12 and H-13 proton resonances also showed 
some overlap but this was not observed for 1B-LSD, which showed a clear 
separation at 7.36 and 7.31 ppm (Table 1). As far as the comparison with the isomer 
1P-ETH-LAD was concerned, the main changes observed related to the differences 
associated with the acyl group and the N6-ethyl (1P-ETH-LAD) to N6-methyl (1B-
LSD) transformation. The proton NMR spectrum, for example, showed the N6-methyl 
singlet (position 17, 2.49 ppm) resonating closely to the residual solvent peak 
(DMSO) whereas in 1P-ETH-LAD this was absent due to the presence of the N6-
ethyl group. The three methyl groups associated with the amide and acyl groups 
were conveniently separated for 1B-LSD whereas two overlapping multiplets were 
observed previously in the 1P-ETH-LAD proton spectrum reflecting four methyl 
groups (2 x amide, 1 x propanoyl and N6-ethyl). The sextet representing the 
additional methylene unit within the acyl group at 1.73 ppm (Table 1) was absent in 
the spectrum of 1P-ETH-LAD.16 Interestingly, the proton chemical shift for H-5β 
experienced a particular change. In 1P-ETH-LAD, this multiplet was detected at 
3.41–3.34 ppm16 whereas in 1B-LSD, this was recorded at 3.08–3.04 ppm (Table 1) 
as a reflection of the change of substituent on the vicinal nitrogen and because a 
different anisotropic effect of the ethyl group compared to the methyl group. A 
comparison of the 13C chemical shift values between 1P-ETH-LAD and 1B-LSD 
revealed some similarities (e.g. carbonyls and indole carbons) but also some 
differences. For example, in the former the 13C chemical shifts for C-5 and C-7 were 
detected at 58.23 and 50.83 ppm16 whereas in the latter, these were observed at 
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62.32 and 55.84 ppm (Table 1). Another notable downfield shift was noticed for the 
methylene group adjacent to the acyl carbonyl group. In 1P-ETH-LAD, it resonated at 
28.15 ppm16 whereas in 1B-LSD, it was found to resonate at 37.04 ppm (Table 1). 
For a visual comparison, stacked NMR spectra (1B-LSD vs. 1P-ETH-LAD) have 
been included as Supporting Information. 
 
3.2 Head-twitch response 
 
To determine whether 1B-LSD produces LSD-like behavioral effects in vivo, we 
assessed whether it induces the HTR in mice. The HTR was assessed for 30 min 
following administration of 1B-LSD. As shown in Figure 7, 1B-LSD (F(5,25) = 41.31, 
p<0.0001) induced the HTR with an ED50 = 457.6 µg/kg (95% CI 334.9–625.5), which 
is equivalent to 976.7 nmol/kg. In comparison, when tested using similar methods, 
LSD induced the HTR with an ED50 of 132.8 nmol/kg,21 meaning that 1B-LSD has  
about 14% of the potency of LSD.   
 
Based on the results of the HTR experiment, 1B-LSD appears to have a 
hallucinogen-like behavioral profile. Indeed, according to accounts published online, 
ingestion of 1B-LSD can produce LSD-like psychedelic experiences. The HTR data 
also show that replacement of the N1-hydrogen in LSD with a butanoyl group results 
in a substantial reduction of potency. An extra-sum-of-squares F-test confirmed that 
1B-LSD is significantly less potent than LSD in mice (F(1,28)=74.98, p<0.0001). 1P-
LSD also showed reduced potency compared to LSD when evaluated in HTR 
experiments.15 Generally, the potency relationships for hallucinogens in the mouse 
HTR paradigm closely parallel the human hallucinogenic data.27,30,31 Interpretation of 
the HTR potency data, however, is complicated by the possibility that 1B-LSD serves 
as a pro-drug for LSD, as indicated by in vitro assays.12 If 1B-LSD is not the active 
species and must be hydrolyzed to LSD then extrapolation of mouse potency data to 
humans is complicated by the possibility of species differences in metabolic enzymes. 
Nevertheless, although 1B-LSD is not as potent as LSD in mice, it still has relatively 
high potency compared to many other hallucinogens.30-34  
 
4. Conclusion 
 
1-Butanoyl-LSD (1B-LSD) represents the latest addition to the growing number of 
lysergamide-based designer drugs. Analytical characterization confirmed that 1B-
LSD can be differentiated from its isomer 1P-ETH-LAD under various mass spectral 
and chromatographic conditions, infrared spectroscopy, and also by NMR. The 
pharmacological experiments included in this investigation confirmed that 1B-LSD 
has LSD-like behavioral properties, which adds a multidisciplinary dimension to the 
characterization of this new psychoactive substance. Clinical studies are warranted 
to evaluate the potency of 1B-LSD in humans and to define its abuse potential as 
well as the qualitative nature of its effects.  
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Table 1. 1H and 13C NMR data for 1B-LSD hemitartrate (2:1) in DMSO-d6 at 600/150 MHz 
 
No. 13C [δ / ppm] 1H [δ / ppm] 
1 – – 
2 120.50 7.61 (d, J = 1.7 Hz, 1 H) 
3 116.56 – 
4 26.64 2.46 (dd, J = 14.7, 1.9 Hz, 4α-H, 1 H) 
* partially coalescing with H-17.  
3.49 (dd, J = 15.3, 5.4 Hz, 4β-H, 1 H) 
5 62.32 3.08–3.04 (m, H-5β, 1 H) 
6 – – 
7 55.84 3.01 (dd, J = 11.1, 4.9 Hz, H-7α, 1 H) 
2.61 (t, J = 10.8 Hz, H-7β, 1 H) 
8 39.42 3.84–3.80 (m, H-8α, 1 H)  
9 122.33 6.35 (s, 1 H) 
10 133.99 – 
11 128.30 – 
12 117.05 7.36 (d, J = 7.4 Hz, 1 H) 
13 126.40 7.31 (t, J = 7.7 Hz, 1 H) 
14 115.30 8.01 (d, J = 7.9 Hz, 1 H) 
15 133.63 – 
16 128.05 – 
17 43.63 2.49 (s, 3 H)  
*partially coalescing with 4α and DMSO peak 
18 170.89 – 
19 – – 
20 42.05 3.45 (q, J = 7.1 Hz, 2 H)  
20 39.89 3.32 (AB qq, J20,20 = 13.9, J20,21 = 7.0 Hz, 2 H)  
*peaks are coalescing with broad water signal 
21 15.31 1.19 (t, J = 7.1 Hz, 3 H) 
21 13.54 1.07 (t, J = 7.0 Hz, 3 H) 
22 172.19 – 
23 – – 
24 37.04 2.97 (t, J = 7.2 Hz, 2 H) 
25 18.13 1.73 (sex, J = 7.3 Hz, 2 H) 
26 14.01 1.00 (t, J = 7.4 Hz, 3 H) 
TA a 173.75 – 
TA a 72.45 4.24 (s, ~1.3 H)  
a TA: Tartaric acid.  
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Figure 1. Chemical structures of lysergic acid diethylamide (LSD) and various 1-acyl 
analogs that emerged as research chemicals. 1B-LSD represents the latest addition 
to the product catalog.   
 
 
 
 
 
Figure 2. Electron ionization mass spectrum of 1B-LSD. 
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Figure 3. Proposed fragmentation pathways for 1B-LSD following electron ionization. 
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Figure 3. Continued. Proposed fragmentation pathways for 1B-LSD following 
electron ionization.
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Figure 4. Gas chromatography-solid state-infrared spectrum of 1B-LSD. Top: entire 
scan range. Bottom: partial scan range.  
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Figure 5. (A): Quadrupole time-of-flight tandem mass spectrum obtained from 1B-
LSD. (B): Single quadrupole mass spectrum of 1B-LSD following in-source collision-
induced-dissociation. (C): Insert in (B): HPLC single ion monitoring using the 
protonated molecule at m/z 394. (D): UV full scan spectrum using HPLC-DAD 
analysis. (E): HPLC-UV chromatogram. 
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Figure 6. Proposed formation of product ions following collision-induced dissociation 
of 1B-LSD under QTOF-MS/MS conditions.  
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Figure 6. Continued. Proposed formation of product ions following collision-induced 
dissociation of 1B-LSD under QTOF-MS/MS conditions. The exact mass of m/z 251 
ion was confirmed by a separate HR-MS/MS method (spectrum in supporting 
information).  
 
 
 
 
Figure 7. Effect of 1B-LSD on the head twitch response. Data are presented as 
group means ± SEM for the entire 30-min test session (Left panel), as well as group 
means during 5-min time blocks (Right panel). *p<0.01, significant difference from 
the vehicle control group (Tukey’s test).   
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